Introduction {#sec1-1}
============

Merkel cell carcinoma (MCC) is a rare and aggressive skin tumor characterized by frequent local relapses, progression of disease, poor quality of life and short survival.^[@ref1]^ MCC was first described by Toker in 1972 as a trabecular carcinoma of the skin,^[@ref2]^ and later as *neuroendocrine carcinoma of the skin* placing it, therefore, in the large family of APUDomas.^[@ref3]^

Treatment of MCC is particularly complex: it involves some expertise from the Clinician, and includes both surgical and pharmacological treatments, often combined, in particular in advanced disease.^[@ref4],[@ref5]^ The spontaneous regression of MCC has been described in a few cases reported in literature. This paper reports a case personally observed by the author, giving final remarks on the possible explanations of this process.

Case Report {#sec1-2}
===========

Male patient 89-years-old, treated with antiaggregating, diuretics and anti-hypertensive, without any autoimmune disease or other immunocompromized status. From a bit of time, the patient has observed the growth of two distinct lesions of the scalp, on the left temporal site and on the vertex, each of them with a size greater than 4 cm ([Figure 1](#fig001){ref-type="fig"}). Approximately two months later the patient undergoes to biopsy of both lesions, and histology shows a Merkel cell carcinoma in both lesions with positive immunohistochemistry for chromogranin A, synaptofisin, CK20, CD117 (spots), neurofilaments (spots), and negative for S100 and TTF1; proliferative index (ki67, MIB1 clone) is equal to 60-70% ([Figure 2](#fig002){ref-type="fig"}). Investigations regarding a potential poly-omavirus status was missed. Later, ^[@ref18]^F-FDGPET-CT showed uptake on both lesions, and on the left site of the neck, this last considered as metastatic site but without cyto-histological confirma tion. Approximately one month after the biopsy, the two tumoral skin sites spontaneously began to shrink in size, thing that excluded a wider excision. Despite the almost complete remission of the skin lesions, the patient started a palliative radiotherapy on primitive lesions of the scalp and on the left neck with a total dose of 40 Gy in 20 sessions for a period of 30 days. After radiotherapy the patient did not other controls. After 24 months from the biopsy the disease is totally regressed ([Figure 3](#fig003){ref-type="fig"}).

Discussion {#sec1-3}
==========

MCC is a highly aggressive skin tumor which rapidly metastasizes with disappointing survival rates close to 50% of cases after 3-year.^[@ref6]^ The incidence of MCC is about 2/1.000.000 in Caucasians and 0.1/1.000.000 in black Americans. The average age of onset is the late 60s, with less than 5% occurring in people under the 50 years of age and the highest incidence over the 85-years-old age group.^[@ref7]^ About 50% of MCCs occurs on the head and neck, 40% on the extremities, and the remaining on the trunk. Sex incidence appears to be equal.^[@ref7]^

Spontaneous regression of MCC is exceedingly rare, and highlights the potentially capricious nature of MCC. As far as we know, a little but not inconsistent number of previous cases has been reported in Literature, so as to speculate that this kind of feature might be not so rare ([Table 1](#table001){ref-type="table"}).^[@ref8]^ In fact, considering the prevalence of MCC in over 600 cases reported in literature,^[@ref30]^ the estimated prevalence of spontaneous regression appears to be greater than expected (1.7-3% of cases).^[@ref21]^ In most cases regression of MCC was preceded by a biopsy of the lesion, as in the present case: it was also suggested a potential stimulation of the immune system.^[@ref31]^ It has been reported that dense clusters of lymphocytes are found within tumor nests;^[@ref10]^ some reports found that CD4+ and CD8+ cells has heavily infiltrated around the tumor nests, via immunophenotypic analysis of the infiltrated lymphocytes.^[@ref10],[@ref12],[@ref16],[@ref31]^ These findings suggest the role of T-cell mediated immune response in the development of tumor regression resulting in apoptosis and cellular necrosis:^[@ref19]^ it was also reported that intratumoral CD3+ (and CD8+) cell infiltration is associated with improved overall survival in a Finnish MCC cohort.^[@ref32]^ Regarding the role of T-cell mediated immune response in tumor regression, of a certain interest could be the potential role of diet with the aim to enhance the antiproliferative response via an immune-mediated mechanism. Dietary supplements as vitamin C, turmeric, probiotics, cod liver oil, organic vegetables, and mushroom, in particular Trametes versicolor, can elicit Natural Killer activity increasing numbers of CD8+ T-cells and CD19+ B-cells.^[@ref33]^ It should be noted that, in the reported case, regression of MCC begins approximately one month after the biopsy, and certainly before radiation treatment. Therefore, we can support that the regression of the lesions is mediated by an immune response stimulated by biopsy.

The biggest number of cases of complete spontaneous regression of MCC have been described in the head and neck, mostly with a lesion of size equal or less than 2 cm.^[@ref7]^ It was found a significant difference in the incidence of regressing MCC between males and females, with a prevalence for females with 77% of cases.^[@ref19]^ Regression, once initiated, was lasting between 1 and 5 months:^[@ref7]^ in the present case, regression lasts from 24 months.

A little series of partial spontaneous regression of MCC is reported by Vesely *et al*., 2008.^[@ref7]^ Eleven cases are described in the Literature with the longest follow up of five years. In this series the most common site was the cheek. This series should be separated from cases of complete regressions, in order to avoid confusion and to prevent a wrong estimate of prevalence.

Conclusions {#sec1-4}
===========

Spontaneous complete regression is a significant event in MCC. A small number of cases of regression has been described in literature, to which we have added a further case. Many of these events began shortly after biopsy, and in some cases lymphocytic infiltration was described. This fact suggests that MCC can be responsive to immunological reactions. In fact, MCC is highly linked with T lymphocyte immune suppression in epidemiologic studies, and CD8+ T cell infiltration into MCC tumors has been shown to be strongly predictive of improved survival. Some Authors have observed, however, that biopsy does not commonly determine the induction of CD8 + lymphocyte infiltration into the tumor, and this fact causes a different survival.^[@ref34]^ Further research about mechanism of spontaneous regression, the role of immune response and also of dietary supplements, could contribute to improve the knowledge about biology of MCC in order to offer a better expectation of prognosis.

I am grateful to Marco Ungari, MD, pathologist at the Hospital in Cremona, for his valuable contribution.

![The two lesions before biopsy.](rt-2015-4-5961-g001){#fig001}

![Histological and immunohistochemical pictures of Merkel cell carcinoma. A) Hematoxylin and Eosin staining; B) chromogranin A; C) synaptofisin; D) CK20; E) CD117; F) neurofilaments; G) Ki67-MIB1](rt-2015-4-5961-g002){#fig002}

![Vertex lesion after 24 months](rt-2015-4-5961-g003){#fig003}

###### 

Complete spontaneous regression in Merkel cell carcinoma described in literature.

  Author                               Year   Country       Sex   Age   Primary site   Size (mm)   Follow up
  ------------------------------------ ------ ------------- ----- ----- -------------- ----------- -----------
  O'Rourke *et al.*^[@ref8]^           1986   Australia     F     90    Cheek          20          18 m
  Bayrou *et al.*^[@ref9]^             1991   France        F     69    Temple         \<20        15 y
  Kayashima *et al.*^[@ref10]^         1991   Japan         F     68    Forehead       16×16       11 y
  Kayashima *et al.*^[@ref10]^         1991   Japan         F     86    Cheek          \<20        36 m
  Djilali-Bouzina *et al.*^[@ref11]^   1992   France        F     83    Cheek          ND          12 m
  Duncan *et al.*^[@ref12]^            1993   USA           M     79    Scalp          12×15       28 m
  Hashimoto *et al.*^[@ref13]^         1993   Japan         F     69    Cheek          15×10       1 y
  Tanita *et al.*^[@ref14]^            1996   Japan         F     75    Cheek          30×30       1 y
  Yanguas *et al.*^[@ref15]^           1997   Spain         M     65    Ear            30×30       18 m
  Connelly *et al.*^[@ref16]^          1997   USA           M     85    Forehead       14          50 m
  Satoh *et al.*^[@ref17]^             1997   Japan         M     87    Cheek          \<20        2 m
  Brown *et al.*^[@ref18]^             1999   USA           M     89    Scalp          9×9         33 m
  Maruo *et al.*^[@ref19]^             2000   Japan         F     82    Cheek          12×10       12 m
  Connelly *et al.*^[@ref20]^          2000   France        F     71    Cheek          \>20        11 m
  Sais *et al.*^[@ref21]^              2002   Spain         F     78    Thigh          24          40 m
  Junquera *et al.*^[@ref22]^          2005   Spain         F     79    Cheek          30×25       3 m
  Kubo *et al.*^[@ref23]^              2007   Japan         F     87    Cheek          50          6 m
  Vesely *et al.*^[@ref7]^             2008   Canada        F     67    Cheek          29×23       6 m
  Missotten *et al.*^[@ref24]^         2008   Netherlands   M     90    Eyelid         \<20        18 m
  Karkos *et al.*^[@ref25]^            2009   England       F     79    Nose/Neck      50×50       30 m
  Ciudad *et al.*^[@ref26]^            2010   Spain         F     86    Cheek          22×12       18 m
  Ciudad *et al.*^[@ref26]^            2010   Spain         M     92    Scalp          30×25       23 m
  Hassan *et al.*^[@ref27]^            2010   Ireland       F     60    Groin          30×45       4 y
  Wooff *et al.*^[@ref28]^             2010   Canada        F     94    Eyebrow        40          33 m
  Val-Bernal *et al.*^[@ref29]^        2011   Spain         F     86    Forearm        33×20       10 w

F, Female; M, Male; ND, Not Done; w, week; m, month; y, year. Adapted from Vesley *et al.*,2008.^[@ref7]^
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